Background Pituitary tumours are common and easily treated by surgery or medical
treatment in most cases. However, a small subset of pituitary tumours does not respond to …

Pituitary adenomas are common intracranial tumors that are mainly considered as benign.
Rarely, these tumors can exhibit an aggressive behavior, characterized by gross invasion of …

Context/Objective: Locally aggressive pituitary tumors (LAPT) and pituitary carcinomas
respond poorly to conventional therapy and cytotoxic drugs. Temozolomide (TMZ) is an oral …

Objectives Only few retrospective studies have reported an efficacy rate of temozolomide
(TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated …

Temozolomide is effective in some patients with progressive pituitary adenoma or
carcinoma. We report a survey study of Italian patients treated with Temozolomide because …

Introduction The term atypical pituitary adenoma (APA) was revised in the 2004 World
Health Organization (WHO) classification of pituitary tumors. However, two of the four …

Eur J Clin Invest 2011; 41 (10): 1133–1148 Abstract Background Aggressive pituitary
tumours are associated with substantial morbidity and mortality. Treatment options are often …

Pituitary carcinomas are rare, accounting for about 0· 2% of all pituitary tumours. They
represent a challenge to clinical practice in both diagnosis and treatment. They may present …

Context: Temozolomide (TMZ) is an alkylating agent and was a first-line chemotherapeutic
agent for malignant gliomas. Recently, TMZ has been documented to be effective against …

Pituitary tumours, the most frequent intracranial tumour, are historically considered benign.
However, various pieces of clinical evidence and recent advances in pathological and …